CELLULAR HEALTH RESEARCH
Semaglutide
10 mg
Support a Healthier, Leaner You.
Semaglutide is a GLP-1 receptor agonist that supports healthy appetite control, glucose metabolism and body composition. It has been extensively studied in human clinical research for weight management and metabolic health. This product is intended for research purposes only.
A Healthier Tomorrow
Semaglutide
10 mg
$100.00 — or Original price was: $100.00.$90.00Current price is: $90.00. / month
Ships within 1-2 Business Days
Subscribe monthly and save 10%
- Ship to Canada,USA & Mexico
- Secure Checkout
- Add to wishlist
PREMIUM QUALITY:
Pharmaceutical-grade
INDEPENDENT TESTING:
Quality verification
BATCH TRANSPARENCY:
Product information
GLOBAL ACCESS:
Canada, USA & Mexico
SUPPORTING A HEALTHIER YOU
Real Benefits for Real Life.
Semaglutide supports key metabolic pathways in the body, helping you feel fuller, make healthier choices and maintain a healthy weight — so you can look, feel and perform your best.
- Helps you feel fuller for longer
- Supports healthy weight loss and body composition
- Aids in healthy blood sugar levels
- Supports heart and metabolic health
- More energy, confidence and an improved quality of life
KEY AREAS OF HUMAN
KEY AREAS OF HUMAN
The Science
Evidence & Mechanism
Semaglutide is a long-acting GLP-1 receptor agonist that mimics the activity of endogenous GLP-1. It binds to GLP-1 receptors in the brain, pancreas and gastrointestinal tract, helping to regulate appetite, slow gastric emptying, promote glucose-dependent insulin secretion and support metabolic health. These combined effects contribute to weight management and overall cardiometabolic benefits observed in human clinical research.
Product Information
| Product Name | Semaglutide |
| Class | GLP-1 receptor agonist |
| Strength | 10 mg |
| Product Format | Lyophilized powder |
| Purity | > 99% (HPLC) |
| Storage | Store refrigerated (2°C–8°C). Protect from light and moisture. |
| Intended Use | Not for human or veterinary use. |
Why Choose Nextgen
- Premium quality research products
- Independent laboratory testing
- Batch transparency
- Consistent quality standards
- Milligram App integration
- Dedicated customer support
FREQUENTLY ASKED QUESTIONS
Your Questions, Answered.
Find quick answers to common questions about this Product.
Semaglutide activates the GLP-1 receptor, a hormone-signalling pathway involved in appetite and glucose control. In STEP 1, adults with overweight or obesity without diabetes lost an average of 14.9% of starting weight over 68 weeks, compared with 2.4% with placebo. Both groups received lifestyle support. The findings concern the clinical formulation and study population.
Controlled appetite research has examined semaglutide’s effects on hunger, eating control and energy consumed at a test meal. These outcomes help explain its weight-management effects. However, a percentage reduction in meal intake is not the same as a percentage reduction in “food noise.” Food-related thoughts need their own defined questions, measurement period and comparison group.
Tirzepatide produced greater average weight loss than semaglutide in the direct SURMOUNT-5 trial in adults without diabetes. Comparisons involving retatrutide or cagrilintide often come from different studies or test a combination. Those results should not be presented as a universal ranking. Receptor counts alone do not determine effectiveness, safety or the best option for an individual.
Nausea and diarrhea were common in STEP 1, and gastrointestinal events led some participants to discontinue treatment. Trial averages do not predict every person’s response or establish long-term effects for a supplier’s research vial. Published clinical results, laboratory purity and the quality of a particular finished medicine answer separate questions.